BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment...

|About: BioLineRx Ltd. (BLRX)|By:, SA News Editor

BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment of schizophrenia, are expected during the week of March 18. The interim analysis, which measures the effect of the drug on cognitive function, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India.